title: Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
abstract: The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study.
authors.affiliation: Department of Allergy and Immunology, Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran; Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Esmailzadeh_ho@yahoo.com.
authors.forename: Hossein
authors.initials: H
authors.lastname: Esmaeilzadeh
authors.affiliation: Department of Allergy and Immunology, Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Nabavi
authors.affiliation: Students' Scientific Research Center, Tehran University of Medical Sciences, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Aryan
authors.affiliation: Department of Allergy and Immunology, Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Saba
authors.initials: S
authors.lastname: Arshi
authors.affiliation: Department of Allergy and Immunology, Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Hassan
authors.initials: MH
authors.lastname: Bemanian
authors.affiliation: Department of Allergy and Immunology, Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Morteza
authors.initials: M
authors.lastname: Fallahpour
authors.affiliation: Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Negar
authors.initials: N
authors.lastname: Mortazavi
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D055963:Asthma, Aspirin-Induced / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D016753:Interleukin-10 / Q000276:immunology; D008297:Male; D009298:Nasal Polyps / Q000188:drug therapy / Q000276:immunology; D012220:Rhinitis / Q000188:drug therapy / Q000276:immunology; D012852:Sinusitis / Q000188:drug therapy / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; C508609:IL10 protein, human; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D007371:Interferon-gamma; D001241:Aspirin
keywords: Aspirin-intolerant asthma; Desensitization; Interferon-gamma; Interleukin-10; Quality of life